Chronic hepatitis C virus (HCV) is a serious problem in the United
States, affecting more than 3 million individuals. Recently, the Food and
Drug Administration approved 2 direct-acting, antiviral protease
inhibitors for the treatment of chronic hepatitis C, genotype 1, which has
greatly affected success rates.